[미래에셋 김승민] 국내 업체 ASCO,임상종양학회 초록 주요 내용

[미래에셋 김승민] 국내 업체 ASCO 초록 주요 내용 

유한양행: https://meetings.asco.org/abstracts-presentations/208278
레이저티닙+아미반타맙. 타그리소, 키모 내성 EGFR 비소세포폐암 CHRYSALIS-2:
ORR 36%(PR 17pt, CR 1pt) mDoR x, 7 pts DOR 6개월 지속. 4회이상치료경험환자 ORR 29%(PT 15pt, 1 CR pt), CBR 55%, mDOR 8.6%
 
엔케이맥스: https://meetings.asco.org/abstracts-presentations/210267
SNK01 단독 용량증대, Average cytotoxicity over 400 average activating receptor expression was greater than 90%. Grade 1 AE 2/50. Best objective response of SD was demonstrated in 7 pts.
https://meetings.asco.org/abstracts-presentations/213056
-
https://meetings.asco.org/abstracts-presentations/208009
SNK+avelumab(바벤시오) 병용 육종암: ORR 13.3%(2/15), SD 3 pts
 
네오이뮨텍:
https://meetings.asco.org/abstracts-presentations/209354
NT-I7 + pembro(키트루다) ORR: SCLC 50%(1/2), MSS CRC 12%(3/25), PDAC 8%(2/26), NSCLC 6%(1/16), TNBC 0%
https://meetings.asco.org/abstracts-presentations/213236
NT-I7 + tisigen(킴리아): -
https://meetings.asco.org/abstracts-presentations/211400
NT-I7 + atezol(티센트릭) 피부암: 1 DLT at DL3, no DLT at DL4, MTD was not reached.
 
에이비온
https://meetings.asco.org/abstracts-presentations/210645
ABN401 고형암: 15 pts, no DLTs. PR 2, SD 5
 
제넥신
https://meetings.asco.org/abstracts-presentations/210032
GX-I7 + pembro(키트루다) 삼중음성유방암: ORR 15.7%(phase 1), 21.2(Phase 2)
 
메드팩토
https://meetings.asco.org/abstracts-presentations/210909
vactosertib+FOLFOX 췌장암: ORR 23.1%(3/13), 5 SD. CBR 61.5%